These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Gyllensten H; Kavaliunas A; Murley C; Alexanderson K; Hillert J; Tinghög P; Friberg E Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319858383. PubMed ID: 31285832 [TBL] [Abstract][Full Text] [Related]
7. Impact of multiple sclerosis phenotypes on burden of disease in Finland. Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776 [No Abstract] [Full Text] [Related]
8. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study. Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609 [TBL] [Abstract][Full Text] [Related]
9. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750 [TBL] [Abstract][Full Text] [Related]
10. Economic burden of multiple sclerosis in a population with low physical disability. García-Domínguez JM; Maurino J; Martínez-Ginés ML; Carmona O; Caminero AB; Medrano N; Ruíz-Beato E; BMC Public Health; 2019 May; 19(1):609. PubMed ID: 31109317 [TBL] [Abstract][Full Text] [Related]
11. Income in Multiple Sclerosis Patients with Different Disease Phenotypes. Kavaliunas A; Manouchehrinia A; Danylaite Karrenbauer V; Gyllensten H; Glaser A; Alexanderson K; Hillert J PLoS One; 2017; 12(1):e0169460. PubMed ID: 28081163 [TBL] [Abstract][Full Text] [Related]
12. Profile of Polish patients with primary progressive multiple sclerosis. Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082 [TBL] [Abstract][Full Text] [Related]
13. A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Salter A; Thomas NP; Tyry T; Cutter GR; Marrie RA Mult Scler; 2018 Jun; 24(7):951-962. PubMed ID: 28524746 [TBL] [Abstract][Full Text] [Related]
14. High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study. Tinghög P; Hillert J; Kjeldgård L; Wiberg M; Glaser A; Alexanderson K Mult Scler; 2013 Dec; 19(14):1923-30. PubMed ID: 23652218 [TBL] [Abstract][Full Text] [Related]
15. Sick-leave track record and other potential predictors of a disability pension. A population based study of 8,218 men and women followed for 16 years. Wallman T; Wedel H; Palmer E; Rosengren A; Johansson S; Eriksson H; Svärdsudd K BMC Public Health; 2009 Apr; 9():104. PubMed ID: 19368715 [TBL] [Abstract][Full Text] [Related]
16. Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database. Vandhuick O; Payet M; Préaud E; Lortet-Tieulent J; Raguideau F; Chevreuil O; van Hille B; Kwiatkowski A Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1135-1144. PubMed ID: 34165377 [TBL] [Abstract][Full Text] [Related]
17. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. Sampat MP; Berger AM; Healy BC; Hildenbrand P; Vass J; Meier DS; Chitnis T; Weiner HL; Bakshi R; Guttmann CR AJNR Am J Neuroradiol; 2009 Oct; 30(9):1731-9. PubMed ID: 19696139 [TBL] [Abstract][Full Text] [Related]
18. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population. Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679 [TBL] [Abstract][Full Text] [Related]
19. The long-term impact of early treatment of multiple sclerosis on the risk of disability pension. Landfeldt E; Castelo-Branco A; Svedbom A; Löfroth E; Kavaliunas A; Hillert J J Neurol; 2018 Mar; 265(3):701-707. PubMed ID: 29392457 [TBL] [Abstract][Full Text] [Related]
20. High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate. Doesburg D; Vennegoor A; Uitdehaag BMJ; van Oosten BW Mult Scler Relat Disord; 2019 Jun; 31():32-37. PubMed ID: 30901702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]